Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints president of global pharmaceuticals

Luke Miels joins from AstraZeneca

GlaxoSmithKline Luke MielsGlaxoSmithKline has appointed Luke Miels as president of global pharmaceuticals, succeeding Abbas Hussain.

Miels joins the UK-headquartered firm from AstraZeneca, where he is currently executive vice president of AZ's European business. Prior to this, Miels served as executive vice president of global product and portfolio strategy, global medical affairs and corporate affairs.

He moved to AZ from Roche in 2014, having been regional vice president of its Asia-Pacific pharmaceutical operations, based in Shanghai, Singapore, after promotion from vice president and head of metabolism and anemia global marketing for Roche Switzerland.

He also brings management experience from Sanofi's operations in the US, Thailand, New Zealand and Australia to the role.

Emma Walmsley, GSK's chief executive officer designate, said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.

“We are now entering a critical period of commercialisation for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline.

“Luke will bring a strong new voice to the decisions and choices we will have to make for our pharmaceuticals business. I am delighted he has agreed to join GSK and look forward to welcoming him to the executive team.”

26th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics